My Bibliography

select

Imaging EGFR and HER3 through 89Zr-labeled MEHD7945A (Duligotuzumab). Scientific reports. . NIHMSID: NIHMS986862.

select

Viola N, Rarig R, Ouellette W, Doyle R. Synthesis, structure and thermal analysis of the gallium complex of 1,4,7,10-tetraazacyclo-dodecane-N,N′,N″,N‴-tetraacetic acid (DOTA). Polyhedron. 2006 December; 25(18):3457-3462. doi: 10.1016/j.poly.2006.06.039.

select

Viola-Villegas N, Vortherms A, Doyle R. Targeting Gallium to Cancer Cells through the Folate Receptor. Drug Target Insights. 2008 March; 3:DTI.S651-. doi: 10.4137/DTI.S651.

select

Viola-Villegas N, Rabideau AE, Cesnavicious J, Zubieta J, Doyle RP. Targeting the folate receptor (FR): imaging and cytotoxicity of ReI conjugates in FR-overexpressing cancer cells. ChemMedChem. 2008 Sep;3(9):1387-94. doi: 10.1002/cmdc.200800125. PubMed PMID: 18651631.

select

Viola‐Villegas N, Rabideau A, Cesnavicious J, Zubieta J, Doyle R. Targeting the Folate Receptor (FR): Imaging and Cytotoxicity of Re <sup>I</sup> Conjugates in FR‐Overexpressing Cancer Cells. ChemMedChem. 2008 September; 3(9):1387-1394. doi: 10.1002/cmdc.200800125.

select

Viola-Villegas, N., Vortherms, A., Doyle, R.P.. Targeting gallium to cancer cells through the folate receptor. Drug Target Insights. 2008; 2008(3):13-25.

select

Viola-Villegas N, Doyle R. The coordination chemistry of 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (H4DOTA): Structural overview and analyses on structure–stability relationships. Coordination Chemistry Reviews. 2009 July; 253(13-14):1906-1925. doi: 10.1016/j.ccr.2009.03.013.

select

Viola-Villegas N, Rabideau AE, Bartholomä M, Zubieta J, Doyle RP. Targeting the cubilin receptor through the vitamin B(12) uptake pathway: cytotoxicity and mechanistic insight through fluorescent Re(I) delivery. J Med Chem. 2009 Aug 27;52(16):5253-61. doi: 10.1021/jm900777v. PubMed PMID: 19627091.

select

Janjigian YY, Viola-Villegas N, Holland JP, Divilov V, Carlin SD, Gomes-DaGama EM, Chiosis G, Carbonetti G, de Stanchina E, Lewis JS. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. J Nucl Med. 2013 Jun;54(6):936-43. doi: 10.2967/jnumed.112.110239. Epub 2013 Apr 11. PubMed PMID: 23578997; PubMed Central PMCID: PMC4967936.

select

Viola-Villegas NT, Rice SL, Carlin S, Wu X, Evans MJ, Sevak KK, Drobjnak M, Ragupathi G, Sawada R, Scholz WW, Livingston PO, Lewis JS. Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology. J Nucl Med. 2013 Nov;54(11):1876-82. doi: 10.2967/jnumed.113.119867. Epub 2013 Sep 12. PubMed PMID: 24029655; PubMed Central PMCID: PMC4274751.

select

Emmetiere F, Irwin C, Viola-Villegas NT, Longo V, Cheal SM, Zanzonico P, Pillarsetty N, Weber WA, Lewis JS, Reiner T. (18)F-labeled-bioorthogonal liposomes for in vivo targeting. Bioconjug Chem. 2013 Nov 20;24(11):1784-9. doi: 10.1021/bc400322h. Epub 2013 Nov 7. PubMed PMID: 24180480; PubMed Central PMCID: PMC3903177.

select

Zeglis BM, Houghton JL, Evans MJ, Viola-Villegas N, Lewis JS. Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals. Inorg Chem. 2014 Feb 17;53(4):1880-99. doi: 10.1021/ic401607z. Epub 2013 Dec 6. PubMed PMID: 24313747; PubMed Central PMCID: PMC4151561.

select

Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, Weitsman G, Barber P, Vojnovic B, Ellis H, Morse N, Viola-Villegas NT, Bosch A, Juric D, Hazra S, Singh S, Kim P, Bergamaschi A, Maheswaran S, Ng T, Penault-Llorca F, Lewis JS, Carey LA, Perou CM, Baselga J, Scaltriti M. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal. 2014 Mar 25;7(318):ra29. doi: 10.1126/scisignal.2005125. PubMed PMID: 24667376; PubMed Central PMCID: PMC4283215.

select

Viola-Villegas NT, Carlin SD, Ackerstaff E, Sevak KK, Divilov V, Serganova I, Kruchevsky N, Anderson M, Blasberg RG, Andreev OA, Engelman DM, Koutcher JA, Reshetnyak YK, Lewis JS. Understanding the pharmacological properties of a metabolic PET tracer in prostate cancer. Proc Natl Acad Sci U S A. 2014 May 20;111(20):7254-9. doi: 10.1073/pnas.1405240111. Epub 2014 May 1. PubMed PMID: 24785505; PubMed Central PMCID: PMC4034234.

select

Viola-Villegas NT, Sevak KK, Carlin SD, Doran MG, Evans HW, Bartlett DW, Wu AM, Lewis JS. Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives. Mol Pharm. 2014 Nov 3;11(11):3965-73. doi: 10.1021/mp500164r. Epub 2014 May 6. PubMed PMID: 24779727; PubMed Central PMCID: PMC4224519.

select

Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, Minuesa G, Morse N, Rodón J, Ibrahim Y, Cortes J, Perez-Garcia J, Galvan P, Grueso J, Guzman M, Katzenellenbogen JA, Kharas M, Lewis JS, Dickler M, Serra V, Rosen N, Chandarlapaty S, Scaltriti M, Baselga J. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med. 2015 Apr 15;7(283):283ra51. doi: 10.1126/scitranslmed.aaa4442. PubMed PMID: 25877889; PubMed Central PMCID: PMC4433148.

select

Demoin DW, Wyatt LC, Edwards KJ, Abdel-Atti D, Sarparanta M, Pourat J, Longo VA, Carlin SD, Engelman DM, Andreev OA, Reshetnyak YK, Viola-Villegas N, Lewis JS. PET Imaging of Extracellular pH in Tumors with (64)Cu- and (18)F-Labeled pHLIP Peptides: A Structure-Activity Optimization Study. Bioconjug Chem. 2016 Sep 21;27(9):2014-23. doi: 10.1021/acs.bioconjchem.6b00306. Epub 2016 Jul 21. PubMed PMID: 27396694; PubMed Central PMCID: PMC5034329.

select

McKnight B, Viola-Villegas N. Abstract 2860: 89Zr-trastuzumab immunoPET imaging to monitor src status after treatment in HER2 breast cancer. Cancer Research. 2017 July; 77(13_Supplement):2860-2860. doi: 10.1158/1538-7445.AM2017-2860.

select

Kuda-Wedagedara ANW, Workinger JL, Nexo E, Doyle RP, Viola-Villegas N. (89)Zr-Cobalamin PET Tracer: Synthesis, Cellular Uptake, and Use for Tumor Imaging. ACS Omega. 2017 Oct 31;2(10):6314-6320. doi: 10.1021/acsomega.7b01180. Epub 2017 Oct 2. PubMed PMID: 29104950; PubMed Central PMCID: PMC5664145.

select

McFall T, McKnight B, Rosati R, Kim S, Huang Y, Viola-Villegas N, Ratnam M. Progesterone receptor A promotes invasiveness and metastasis of luminal breast cancer by suppressing regulation of critical microRNAs by estrogen. J Biol Chem. 2018 Jan 26;293(4):1163-1177. doi: 10.1074/jbc.M117.812438. Epub 2017 Nov 21. PubMed PMID: 29162724; PubMed Central PMCID: PMC5787796.

select

McKnight BN, Viola-Villegas NT. (89) Zr-ImmunoPET companion diagnostics and their impact in clinical drug development. J Labelled Comp Radiopharm. 2018 Jul;61(9):727-738. doi: 10.1002/jlcr.3605. Epub 2018 Mar 12. Review. PubMed PMID: 29341222; PubMed Central PMCID: PMC6050145.

select

McKnight BN, Kuda-Wedagedara ANW, Sevak KK, Abdel-Atti D, Wiesend WN, Ku A, Selvakumar D, Carlin SD, Lewis JS, Viola-Villegas NT. Imaging EGFR and HER3 through (89)Zr-labeled MEHD7945A (Duligotuzumab). Sci Rep. 2018 Jun 13;8(1):9043. doi: 10.1038/s41598-018-27454-6. PubMed PMID: 29899472; PubMed Central PMCID: PMC5998059.

select

Gibson HM, McKnight BN, Malysa A, Dyson G, Wiesend WN, McCarthy CE, Reyes J, Wei WZ, Viola-Villegas NT. IFNγ PET Imaging as a Predictive Tool for Monitoring Response to Tumor Immunotherapy. Cancer Res. 2018 Oct 1;78(19):5706-5717. doi: 10.1158/0008-5472.CAN-18-0253. Epub 2018 Aug 16. PubMed PMID: 30115693; PubMed Central PMCID: PMC6443251.

select

Erratum for the Research Article: "PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer" by A. Bosch, Z. Li, A. Bergamaschi, H. Ellis, E. Toska, A. Prat, J. J. Tao, D. E. Spratt, N. T. Viola-Villegas, P. Castel, G. Minuesa, N. Morse, J. Rodón, Y. Ibrahim, J. Cortes, J. Perez-Garcia, P. Galvan, J. Grueso, M. Guzman, J. A. Katzenellenbogen, M. Kharas, J. S. Lewis, M. Dickler, V. Serra, N. Rosen, S. Chandarlapaty, M. Scaltriti, J. Baselga. Sci Transl Med. 2018 Oct 24;10(464). doi: 10.1126/scitranslmed.aav7516. PubMed PMID: 30355802.

select

McKnight BN, Viola-Villegas NT. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with (89)Zr-trastuzumab PET imaging. Breast Cancer Res. 2018 Oct 25;20(1):130. doi: 10.1186/s13058-018-1055-2. PubMed PMID: 30359299; PubMed Central PMCID: PMC6203283.

select

Gibson HM, Viola NT. The importance of examining an active immune system during immunotherapy. Oncotarget. 2019 Jan 15;10(5):559-560. doi: 10.18632/oncotarget.26580. eCollection 2019 Jan 15. PubMed PMID: 30728906; PubMed Central PMCID: PMC6355172.

select

Workinger JL, Kuda-Wedagedara ANW, Julin MM, White JM, Nexo E, Viola NT, Doyle RP. Systemically Administered Plant Recombinant Holo-Intrinsic Factor Targets the Liver and is not Affected by Endogenous B12 levels. Sci Rep. 2019 Aug 22;9(1):12269. doi: 10.1038/s41598-019-48555-w. PubMed PMID: 31439908; PubMed Central PMCID: PMC6706418.

select

Pereira PMR, Ragupathi A, Shmuel S, Mandleywala K, Viola NT, Lewis JS. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer. Mol Pharm. 2020 Jan 6;17(1):327-337. doi: 10.1021/acs.molpharmaceut.9b01091. Epub 2019 Dec 19. PubMed PMID: 31804840; PubMed Central PMCID: PMC7218915.

select

White JM, Kuda-Wedagedara AN, Wicker MN, Spratt DE, Schopperle WM, Heath E, Viola NT. Detecting TRA-1-60 in Cancer via a Novel Zr-89 Labeled ImmunoPET Imaging Agent. Mol Pharm. 2020 Apr 6;17(4):1139-1147. doi: 10.1021/acs.molpharmaceut.9b01181. Epub 2020 Feb 28. PubMed PMID: 32069422; PubMed Central PMCID: PMC7249247.

select

McKnight BN, Kim S, Boerner JL, Viola NT. Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer. Breast Cancer Res. 2020 Apr 15;22(1):37. doi: 10.1186/s13058-020-01270-1. PubMed PMID: 32295603; PubMed Central PMCID: PMC7160960.

select

White JM, Keinänen OM, Cook BE, Zeglis BM, Gibson HM, Viola NT. Removal of Fc Glycans from [(89)Zr]Zr-DFO-Anti-CD8 Prevents Peripheral Depletion of CD8(+) T Cells. Mol Pharm. 2020 Jun 1;17(6):2099-2108. doi: 10.1021/acs.molpharmaceut.0c00270. Epub 2020 May 12. PubMed PMID: 32330387; PubMed Central PMCID: PMC7307332.

select

McCarthy CE, White JM, Viola NT, Gibson HM. In vivo Imaging Technologies to Monitor the Immune System. Front Immunol. 2020;11:1067. doi: 10.3389/fimmu.2020.01067. eCollection 2020. Review. PubMed PMID: 32582173; PubMed Central PMCID: PMC7280489.

select

White JM, Escorcia FE, Viola NT. Perspectives on metals-based radioimmunotherapy (RIT): moving forward. Theranostics. 2021;11(13):6293-6314. doi: 10.7150/thno.57177. eCollection 2021. Review. PubMed PMID: 33995659; PubMed Central PMCID: PMC8120204.

select

Mpilla GB, Uddin MH, Al-Hallak MN, Aboukameel A, Li Y, Kim SH, Beydoun R, Dyson G, Baloglu E, Senapedis WT, Landesman Y, Wagner KU, Viola NT, El-Rayes BF, Philip PA, Mohammad RM, Azmi AS. PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus. Mol Cancer Ther. 2021 Oct;20(10):1836-1845. doi: 10.1158/1535-7163.MCT-20-1105. Epub 2021 Jul 12. PubMed PMID: 34253597; PubMed Central PMCID: PMC8492493.

select

Pisaneschi F, Viola NT. Development and Validation of a PET/SPECT Radiopharmaceutical in Oncology. Mol Imaging Biol. 2022 Feb;24(1):1-7. doi: 10.1007/s11307-021-01645-6. Epub 2021 Sep 20. Review. PubMed PMID: 34542804; PubMed Central PMCID: PMC8760224.

select

Hackett JB, Glassbrook JE, Muñiz MC, Bross M, Fielder A, Dyson G, Movahhedin N, McCasland J, McCarthy-Leo C, Gibson HM. A diversity outbred F1 mouse model identifies host-intrinsic genetic regulators of response to immune checkpoint inhibitors. Oncoimmunology. 2022;11(1):2064958. doi: 10.1080/2162402X.2022.2064958. eCollection 2022. PubMed PMID: 35481286; PubMed Central PMCID: PMC9037414.

select

Viola NT, Glassbrook JE, Kalluri JR, Hackett JB, Wicker MN, Sternberg J, Gibson HM. Evaluation of an ImmunoPET Tracer for IL-12 in a Preclinical Model of Inflammatory Immune Responses. Front Immunol. 2022;13:870110. doi: 10.3389/fimmu.2022.870110. eCollection 2022. PubMed PMID: 35634303; PubMed Central PMCID: PMC9130849.

select

Rezazadeh F, Ramos N, Saliganan AD, Barr S, Peraino N, Schomburg F, Rancour D, Viola NT. Evaluation and selection of a lead diabody for interferon-γ PET imaging. Nucl Med Biol. 2022 Nov-Dec;114-115:162-167. doi: 10.1016/j.nucmedbio.2022.06.001. Epub 2022 Jun 17. PubMed PMID: 35753939; PubMed Central PMCID: PMC12344730.

select

Hackett J, Gibson H, Frelinger J, Buntzman A. Using the Collaborative Cross and Diversity Outbred Mice in Immunology. Curr Protoc. 2022 Sep;2(9):e547. doi: 10.1002/cpz1.547. PubMed PMID: 36066328; PubMed Central PMCID: PMC9612550.

select

Choe YS, Vugts DJ, Viola NT. Women in radiopharmaceutical/radiochemical sciences. Nucl Med Biol. 2022 Nov-Dec;114-115:108-114. doi: 10.1016/j.nucmedbio.2022.10.004. Epub 2022 Oct 26. PubMed PMID: 36443145.

select

Perrine SA, Alsharif WF, Harutyunyan A, Kamal S, Viola NT, Gelovani JG. Low- and high-cocaine intake affects the spatial and temporal dynamics of class IIa HDAC expression-activity in the nucleus accumbens and hippocampus of male rats as measured by [18F]TFAHA PET/CT neuroimaging. Addict Neurosci. 2022 Dec;4. doi: 10.1016/j.addicn.2022.100046. Epub 2022 Nov 8. PubMed PMID: 36540409; PubMed Central PMCID: PMC9762729.

select

Rezazadeh F, Ramos N, Saliganan A, Al-Hallak N, Chen K, Mohamad B, Wiesend W, Viola N. Detection of IL23p40 via Positron Emission Tomography Visualized Inflammatory Bowel Disease. [preprint]. 2022 November. doi: 10.1101/2022.11.30.518419.

select

Ran C, Mansfield JR, Bai M, Viola NT, Mahajan A, Delikatny EJ. Practical Guidance for Developing Small-Molecule Optical Probes for In Vivo Imaging. Mol Imaging Biol. 2023 Feb;25(1):240-264. doi: 10.1007/s11307-023-01800-1. Epub 2023 Feb 6. Review. PubMed PMID: 36745354.

select

White JM, Ramos N, Saliganan AD, Chung JY, Bell M, Lindquist J, Conner K, Wiesend WN, Schopperle M, Patrick SM, Kim S, Heath EI, Escorcia FE, Viola NT. Selective ablation of TRA-1-60(+) pluripotent stem cells suppresses tumor growth of prostate cancer. Theranostics. 2023;13(7):2057-2071. doi: 10.7150/thno.78915. eCollection 2023. PubMed PMID: 37153742; PubMed Central PMCID: PMC10157726.

select

Glassbrook JE, Hackett JB, Muñiz MC, Bross M, Dyson G, Movahhedin N, Ullrich A, Gibson HM. Host genetic background regulates the capacity for anti-tumor antibody-dependent phagocytosis. bioRxiv. 2023 May 9;. doi: 10.1101/2023.05.09.540046. PubMed PMID: 37214876; PubMed Central PMCID: PMC10197614.

select

Rezazadeh F, Ramos N, Saliganan AD, Al-Hallak N, Chen K, Mohamad B, Wiesend WN, Viola NT. Detection of IL12/23p40 via PET Visualizes Inflammatory Bowel Disease. J Nucl Med. 2023 Nov;64(11):1806-1814. doi: 10.2967/jnumed.123.265649. Epub 2023 Jul 20. PubMed PMID: 37474270; PubMed Central PMCID: PMC10626378.

select

Rezazadeh F, Kilcline AP, Viola NT. Imaging Agents for PET of Inflammatory Bowel Disease: A Review. J Nucl Med. 2023 Dec 1;64(12):1858-1864. doi: 10.2967/jnumed.123.265935. Review. PubMed PMID: 37918865; PubMed Central PMCID: PMC10690123.

select

Hackett JB, Ramos N, Barr S, Bross M, Viola NT, Gibson HM. Interferon gamma immunoPET imaging to evaluate response to immune checkpoint inhibitors. Front Oncol. 2023;13:1285117. doi: 10.3389/fonc.2023.1285117. eCollection 2023. PubMed PMID: 38130991; PubMed Central PMCID: PMC10735274.

select

Rezazadeh F, Saadat W, Smith R, Pattyn A, Malik M, Yazdani F, Saliganan AD, Mehrmohammadi M, Viola NT. Mild Hyperthermia Enhanced Liposomal Doxorubicin Delivery and CD8(+) T cell Infiltration in Triple Negative Breast Cancer. bioRxiv. 2024 Apr 27;. doi: 10.1101/2024.04.25.591226. PubMed PMID: 38712049; PubMed Central PMCID: PMC11071532.

select

Rezazadeh F, Saadat W, Smith R, Pattyn A, Malik M, Yazdani F, Saliganan A, Mehrmohammadi M, Viola N. Mild Hyperthermia Enhanced Liposomal Doxorubicin Delivery and CD8 <sup>+</sup> T cell Infiltration in Triple Negative Breast Cancer. [preprint]. 2024 April. doi: 10.1101/2024.04.25.591226.